Berlin, Germany, November 10, 2015 / B3C newswire / - BioGenes GmbH, a global leader in host cell protein (HCP) assay development and a recognized partner of pharmaceutical companies all over the world, today announced that it has acquired all outstanding shares from its existing shareholders GUB Unternehmensbeteiligungen GmbH & Co. KGaA and VC Fonds Berlin GmbH for an undisclosed price. The management team consisting of the two founders Dr. Alexander Knoll and Dr. Sergej Ovodov have taken over these shares in a management buy-out (MBO). The acquisition has been finalized on 31 October 2015.
Dr. Alexander Knoll, Managing Director of BioGenes said: "We are delighted to have reached an agreement with the previous shareholders and we would like to take the opportunity to thank them for their loyalty. With their support, BioGenes has been growing strongly over the last years. The MBO will support our future growth strategy by driving innovations for customers and building new strategic partnerships with the aim to further expand our market position as a leader in host cell assay development."
Dagmar Schwertner, Marketing Director of BioGenes said: „BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development and we intend to continue systematically down the path we have started on. High quality standards throughout the whole value chain will of course be ensured in the years ahead.”
About BioGenes
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.
Contact
Dagmar Schwertner-Knoll
Marketing/Sales Director
BioGenes GmbH
+49-30-65762380
This email address is being protected from spambots. You need JavaScript enabled to view it.